JP2023059239A - 抗ブルーライト損傷効果を向上するための薬物を製造するのに用いられるサナギタケ子実体抽出物の使用 - Google Patents
抗ブルーライト損傷効果を向上するための薬物を製造するのに用いられるサナギタケ子実体抽出物の使用 Download PDFInfo
- Publication number
- JP2023059239A JP2023059239A JP2022149436A JP2022149436A JP2023059239A JP 2023059239 A JP2023059239 A JP 2023059239A JP 2022149436 A JP2022149436 A JP 2022149436A JP 2022149436 A JP2022149436 A JP 2022149436A JP 2023059239 A JP2023059239 A JP 2023059239A
- Authority
- JP
- Japan
- Prior art keywords
- pupa
- fruiting body
- mushroom fruiting
- body extract
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 124
- 230000000694 effects Effects 0.000 title claims abstract description 21
- 230000008832 photodamage Effects 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 229940079593 drug Drugs 0.000 title claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 title abstract description 9
- 241001264174 Cordyceps militaris Species 0.000 title abstract description 7
- 235000013399 edible fruits Nutrition 0.000 title abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 94
- 239000007864 aqueous solution Substances 0.000 claims abstract description 23
- 239000000243 solution Substances 0.000 claims abstract description 13
- 241000382353 Pupa Species 0.000 claims description 186
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 133
- 238000000605 extraction Methods 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 14
- 230000037396 body weight Effects 0.000 claims description 12
- 235000021466 carotenoid Nutrition 0.000 description 35
- 150000001747 carotenoids Chemical class 0.000 description 35
- 238000012360 testing method Methods 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 29
- 230000000007 visual effect Effects 0.000 description 29
- 230000035945 sensitivity Effects 0.000 description 27
- 210000000608 photoreceptor cell Anatomy 0.000 description 20
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 14
- 235000012680 lutein Nutrition 0.000 description 14
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 14
- 229960005375 lutein Drugs 0.000 description 13
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 13
- 239000001656 lutein Substances 0.000 description 13
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 238000010992 reflux Methods 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 210000001525 retina Anatomy 0.000 description 7
- 230000006866 deterioration Effects 0.000 description 6
- 230000037406 food intake Effects 0.000 description 5
- 230000011514 reflex Effects 0.000 description 5
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 4
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 238000000585 Mann–Whitney U test Methods 0.000 description 4
- 201000007737 Retinal degeneration Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000004258 retinal degeneration Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000004304 visual acuity Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000007319 Avena orientalis Nutrition 0.000 description 2
- 244000075850 Avena orientalis Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 2
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 2
- 235000019733 Fish meal Nutrition 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241000222350 Pleurotus Species 0.000 description 2
- 241000243650 Tubifex tubifex Species 0.000 description 2
- 235000005811 Viola adunca Nutrition 0.000 description 2
- 240000009038 Viola odorata Species 0.000 description 2
- 235000013487 Viola odorata Nutrition 0.000 description 2
- 235000002254 Viola papilionacea Nutrition 0.000 description 2
- 244000172533 Viola sororia Species 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 235000021120 animal protein Nutrition 0.000 description 2
- 230000009876 antimalignant effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000001360 collision-induced dissociation Methods 0.000 description 2
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 2
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000004467 fishmeal Substances 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000013882 gravy Nutrition 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010993 response surface methodology Methods 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 235000014102 seafood Nutrition 0.000 description 2
- 238000006557 surface reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 241001529400 Cordycipitaceae Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 230000003667 anti-reflective effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000004886 head movement Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000003733 optic disk Anatomy 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013042 tunel staining Methods 0.000 description 1
- 239000010981 turquoise Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明のサナギタケ子実体抽出物の使用は、抗ブルーライト損傷効果を向上するための薬物を製造するのに用いられることができる、また、前記サナギタケ子実体抽出物はエタノール水溶液により、サナギタケ子実体試料を抽出して獲得されるものである。
Claims (14)
- 抗ブルーライト損傷効果を向上するための薬物を製造するのに用いられるサナギタケ子実体抽出物の使用であって、前記サナギタケ子実体抽出物は、エタノール水溶液により、サナギタケ子実体試料を抽出して獲得されるものであることを特徴とするサナギタケ子実体抽出物の使用。
- 前記サナギタケ子実体抽出物が、エタノール濃度が20%以上のエタノール水溶液により、サナギタケ子実体試料を抽出して獲得されるものであることを特徴とする請求項1に記載のサナギタケ子実体抽出物の使用。
- 前記サナギタケ子実体抽出物が、エタノール水溶液により、サナギタケ子実体試料を20~100分抽出して獲得されるものであることを特徴とする請求項1に記載のサナギタケ子実体抽出物の使用。
- 前記サナギタケ子実体抽出物は、エタノール濃度が60%以上のエタノール水溶液により、サナギタケ子実体試料を40~100分の抽出時間で抽出して獲得されるものであることを特徴とする請求項1に記載のサナギタケ子実体抽出物の使用。
- 前記サナギタケ子実体抽出物は、エタノール濃度が62.9%のエタノール水溶液により、サナギタケ子実体試料を88.3分の抽出時間で抽出して獲得されるものであることを特徴とする請求項4に記載のサナギタケ子実体抽出物の使用。
- 前記のサナギタケ子実体抽出物が需要個体に経口投与されることを特徴とする請求項1~5のいずれか1項に記載のサナギタケ子実体抽出物の使用。
- 前記の需要個体はマウス個体であり、前記のサナギタケ子実体抽出物の投与量は1日当たり、10~100mg/kg体重であり、2~30日間連続して投与されることを特徴とする請求項6に記載のサナギタケ子実体抽出物の使用。
- 前記のサナギタケ子実体抽出物の投与量は1日当たり、20mg/kg体重であり、7~22日間連続して需要個体に投与されることを特徴とする請求項7に記載のサナギタケ子実体抽出物の使用。
- 前記のサナギタケ子実体抽出物は1日当たり1~3回の頻度で需要個体に連続して投与されることを特徴とする請求項7に記載のサナギタケ子実体抽出物の使用。
- 前記のサナギタケ子実体抽出物は1日当たり2回の頻度で需要個体に連続して投与されることを特徴とする請求項9に記載のサナギタケ子実体抽出物の使用。
- 前記の需要個体はヒト個体であり、前記のサナギタケ子実体抽出物の投与量は1日当たり、1~10mg/kg体重であり、7~60日間連続して需要個体に投与されることを特徴とする請求項6に記載のサナギタケ子実体抽出物の使用。
- 前記のサナギタケ子実体抽出物の投与量は1日当たり、1~3mg/kg体重であり、7~22日間連続して需要個体に投与されることを特徴とする請求項11に記載のサナギタケ子実体抽出物の使用。
- 前記のサナギタケ子実体抽出物は1日当たり1~3回の頻度で需要個体に連続して投与されることを特徴とする請求項11に記載のサナギタケ子実体抽出物の使用。
- 前記のサナギタケ子実体抽出物は1日当たり2回の頻度で需要個体に連続して投与されることを特徴とする請求項13に記載のサナギタケ子実体抽出物の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW110138183 | 2021-10-14 | ||
TW110138183A TWI772201B (zh) | 2021-10-14 | 2021-10-14 | 北蟲草子實體萃取物用於製造提升抗藍光傷害效應的藥物的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023059239A true JP2023059239A (ja) | 2023-04-26 |
JP7420410B2 JP7420410B2 (ja) | 2024-01-23 |
Family
ID=83439777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022149436A Active JP7420410B2 (ja) | 2021-10-14 | 2022-09-20 | 抗ブルーライト損傷効果を向上するための薬物を製造するのに用いられるサナギタケ子実体抽出物の使用 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP7420410B2 (ja) |
CN (1) | CN115969889B (ja) |
TW (1) | TWI772201B (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI814687B (zh) * | 2023-03-22 | 2023-09-01 | 鼎赫生物科技股份有限公司 | 具有抗藍光功效的北蟲草pa102用於減緩視網膜細胞老化、減緩視網膜細胞病變、修復視網膜損傷的醫藥用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007000064A (ja) * | 2005-06-23 | 2007-01-11 | Nitto Denko Corp | 冬虫夏草新菌株 |
US20190008911A1 (en) * | 2017-07-07 | 2019-01-10 | Grape King Bio Ltd. | Active substances of cordyceps cicadae and its uses in preventing, delaying or treating cataracts |
JP2020029448A (ja) * | 2018-08-24 | 2020-02-27 | 葡萄王生技股▲ふん▼有限公司 | 前眼房/後眼房容積の変化、硝子体液の変化、および/または網膜剥離を予防、遅延、または治療するための組成物を製造するためのコルディセプス・シカダ菌糸体活性物質の使用 |
JP2020141596A (ja) * | 2019-03-06 | 2020-09-10 | 株式会社峯樹木園 | 冬虫夏草子実体の生産方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102696402A (zh) * | 2012-07-04 | 2012-10-03 | 黑龙江大学 | 一种甘草北虫草的培养方法 |
CN104706682B (zh) * | 2013-12-12 | 2018-01-30 | 富裔实业股份有限公司 | 一种中草药萃取物及其用于制备肺癌药物的用途 |
TWI558405B (zh) * | 2015-04-22 | 2016-11-21 | Grape King Bio Ltd | Cicada active material, a preparation method thereof, a pharmaceutical composition comprising the same and a use thereof |
CN105248150B (zh) * | 2015-11-19 | 2017-12-22 | 江苏康能生物工程股份有限公司 | 一种提高蛹虫草子实体中虫草素含量的方法 |
CN108013438A (zh) * | 2017-12-13 | 2018-05-11 | 深圳地天国际生物工程科技有限公司 | 一种虫草保健食品及其制备工艺 |
TW201932122A (zh) * | 2018-01-17 | 2019-08-16 | 明谷農業生技股份有限公司 | 蟲草素之萃取方法及其於製備眼睛保護組成物之用途 |
CN110448565A (zh) * | 2018-05-07 | 2019-11-15 | 明谷农业生技股份有限公司 | 虫草素的萃取方法及其于制备眼睛保护组合物的用途 |
-
2021
- 2021-10-14 TW TW110138183A patent/TWI772201B/zh active
-
2022
- 2022-08-11 CN CN202210966881.7A patent/CN115969889B/zh active Active
- 2022-09-20 JP JP2022149436A patent/JP7420410B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007000064A (ja) * | 2005-06-23 | 2007-01-11 | Nitto Denko Corp | 冬虫夏草新菌株 |
US20190008911A1 (en) * | 2017-07-07 | 2019-01-10 | Grape King Bio Ltd. | Active substances of cordyceps cicadae and its uses in preventing, delaying or treating cataracts |
JP2020029448A (ja) * | 2018-08-24 | 2020-02-27 | 葡萄王生技股▲ふん▼有限公司 | 前眼房/後眼房容積の変化、硝子体液の変化、および/または網膜剥離を予防、遅延、または治療するための組成物を製造するためのコルディセプス・シカダ菌糸体活性物質の使用 |
JP2020141596A (ja) * | 2019-03-06 | 2020-09-10 | 株式会社峯樹木園 | 冬虫夏草子実体の生産方法 |
Non-Patent Citations (2)
Title |
---|
OUYANG, XINLI ET AL.: "Mechanisms of blue light-induced eye hazard and protective measures: a review", BIOMEDICINE & PHARMACOTHERAPY, vol. Volume 130, 110577, JPN6023031301, October 2020 (2020-10-01), pages 1 - 8, ISSN: 0005119957 * |
ZHANG, MING-LIANG ET AL.: "Extraction and anti-oxidative activity of yellow pigment from Cordyceps militaris", MYCOSYSTEMA, vol. 37, no. 6, JPN6023031300, 2018, pages 761 - 771, ISSN: 0005119958 * |
Also Published As
Publication number | Publication date |
---|---|
CN115969889B (zh) | 2024-05-31 |
JP7420410B2 (ja) | 2024-01-23 |
TW202315643A (zh) | 2023-04-16 |
CN115969889A (zh) | 2023-04-18 |
TWI772201B (zh) | 2022-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jannel et al. | Novel insights into the biotechnological production of Haematococcus pluvialis-derived astaxanthin: Advances and key challenges to allow its industrial use as novel food ingredient | |
US6316002B1 (en) | Germination activated red Ganoderma lucidum spores and method for producing the same | |
KR101467903B1 (ko) | 흑미의 담자균류균사 발효 및 생물전환공정을 통해 생산된 면역증강제 | |
CN101325961A (zh) | 藻类的和藻类提取物饮食补充组合物 | |
JP6978325B2 (ja) | キサントフィルとヒシ属植物の加工物を含有する組成物 | |
JP2023059239A (ja) | 抗ブルーライト損傷効果を向上するための薬物を製造するのに用いられるサナギタケ子実体抽出物の使用 | |
JP2021080270A (ja) | キサントフィルとヒシ属植物の加工物を含有する組成物 | |
KR20180011777A (ko) | 망막 색소 상피 세포를 보호하기 위한 노르빅신 함유 조성물 | |
WO2024055795A1 (zh) | 一种具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 | |
CN1405314A (zh) | 隐孔菌发酵产物及其制备方法和应用 | |
CN109232758B (zh) | 一种榆黄蘑菌糠多糖及其提取工艺和应用 | |
KR102182238B1 (ko) | 진세노사이드 Rd를 강화한 효소처리 홍삼추출물을 포함하는 안구건조증 개선용 조성물 및 이의 제조방법 | |
KR20120069221A (ko) | 봉독조성물 | |
JP4109572B2 (ja) | 冬虫夏草菌糸体の培養方法及び組成物 | |
US20010009903A1 (en) | Augmentation method for antitumor activity of substance containing amygdalin, composition containing augmented amygdalin contained substance, method for assessing antitumor efficacy of treatment for amygdalin contained substance and method for assessing antitumor, substance containing amygdalin | |
EL-Tantawi et al. | Evaluation of the side effects of different doses of spirulina on various organs in rats: Biochemical, histological and histochemical assessment | |
EP1968575B1 (en) | Immunomodulatory pharmaceutical composition containing a combination of three coumarinolignoids | |
CN1261452C (zh) | 用鳖或/和龟的血清提取的糖缀合物chb和制备工艺及其在制药中的应用 | |
WO2020045647A1 (ja) | 血糖値上昇抑制剤、糖尿病抑制剤、及び食品組成物 | |
EP1535619B1 (en) | Poria extract devoid of secolanostane derivatives comprising lanostane derivatives for immunity enhancement | |
Mbiri et al. | Research Article Terminalia brownii Fresen: Stem Bark Dichloromethane Extract Alleviates Pyrogallol-Induced Suppression of Innate Immune Responses in Swiss Albino Mice | |
JP2022097330A (ja) | ヤマブシタケ由来のngf合成促進物質単離のための菌床栽培および製造方法 | |
CN106491688A (zh) | 一种萝卜缨的活性部位及其用途 | |
JP4928060B2 (ja) | イザリア型虫草由来のサイトカイン産生増強剤 | |
CN111821372A (zh) | 紫洋葱萃取物与其化合物用于制备保护眼睛的组合物的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220920 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230801 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231020 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231212 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231228 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7420410 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |